MedTrace Logo

Anticholinergic Therapy for Overactive Bladder in Parkinson's Disease

NCT00892450 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2014-10-03

No results posted yet for this study

Summary

The purpose of this research study is to investigate the cognitive (thinking, memory, knowledge, intelligence) side effects of two medications commonly used to treat overactive bladder (OAB) symptoms in veteran patients with Parkinson's disease (PD) seen at the Philadelphia PADRECC.

Conditions

Interventions

DRUG

Oxybutynin and darifenacin

Participants with overactive bladder will take each medication for 4 weeks.

Sponsors & Collaborators

Principal Investigators

  • Jayne R Wilkinson, MD · VA Medical Center, Philadelphia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-05-31
Primary Completion
2014-09-30
Completion
2014-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00892450 on ClinicalTrials.gov